Prosecution Insights
Last updated: April 19, 2026

Examiner: D' AMBROSIO, THEA

Tech Center 1600 • Art Units: 1654 1675

This examiner grants 55% of resolved cases

Performance Statistics

55.4%
Allow Rate
-4.6% vs TC avg
526
Total Applications
+56.5%
Interview Lift
1268
Avg Prosecution Days
Based on 480 resolved cases, 2023–2026

Rejection Statute Breakdown

5.2%
§101 Eligibility
10.9%
§102 Novelty
34.1%
§103 Obviousness
25.7%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18045317 Antagonism of the VIP Signaling Pathway Non-Final OA Emory University
17279228 GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF Non-Final OA TAKEDA PHARMACEUTICAL COMPANY LIMITED
17286857 Netrin-1 Compounds and Compositions Thereof for Treating Pulmonary Hypertension Final Rejection The Regents of the University of California
17904529 OPTIMIZATION OF PEPTIDE-MELANIN BINDING Final Rejection UNIVERSITÉ PARIS CITÉ
18030250 COMPOSITIONS AND METHODS OF TREATING A PI3K MEDIATED DISEASE Non-Final OA VIRGINIA TECH INTELLECTUAL PROPERTIES, INC.
17631934 AGENT FOR PREVENTING OR TREATING MILD COGNITIVE IMPAIRMENT Non-Final OA NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
17631824 MHC CLASS II MOLECULES AND METHODS OF USE THEREOF Final Rejection University Health Network
17631820 MHC CLASS II MOLECULES AND METHODS OF USE THEREOF Non-Final OA University Health Network
18004233 COMPOSITIONS HAVING NEUROREGENERATIVE APPLICATIONS Non-Final OA GRIFOLS WORLDWIDE OPERATIONS LIMITED
17629338 A SERIES OF INJECTABLE HYDROGELS SELF-ASSEMBLED FROM SHORT PEPTIDES FOR VARIOUS BIOMEDICAL APPLICATIONS Non-Final OA Agency for Science, Technology and Research
17271991 COMPOSITIONS AND METHODS FOR PROTEIN DETECTION Non-Final OA Syngenta Participations AG
17290264 Native whey protein for improving intestinal maturation Non-Final OA N.V. Nutricia
17312296 AMINO ACID HAVING FUNCTIONAL GROUP CAPABLE OF INTERMOLECULAR HYDROGEN BONDING, PEPTIDE COMPOUND CONTAINING SAME AND METHOD FOR PRODUCTION THEREOF Final Rejection Chugai Seiyaku Kabushiki Kaisha
18602513 COMPOSITIONS AND METHOD FOR OPTIMIZED PEPTIDE VACCINES USING RESIDUE OPTIMIZATION Non-Final OA Think Therapeutics, Inc.
17089220 COMPOSITIONS AND METHODS FOR TREATMENT OR PREVENTION OF SKIN DISEASES AND DISORDERS WITH LEKTI Non-Final OA Azitra Inc
18352101 METHODS AND COMPOSITIONS FOR THE TREATMENT OF WOUNDS Non-Final OA Imperial College Innovations Limited
18003123 FUSION PROTEIN COMPRISING ANTI-LAG-3 ANTIBODY AND IL-2, AND USE THEREOF Non-Final OA GI INNOVATION, INC.
17911368 PHOTORESPONSIVE PROTEIN FOR COLOR RECOGNITION AND USE THEREOF Non-Final OA NAGOYA INSTITUTE OF TECHNOLOGY
18136803 Sialylated Glycoproteins Final Rejection Momenta Pharmaceuticals, Inc.
17309626 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP Final Rejection BicycleTx Limited
17633836 STABILIZING BUFFER FOR FACTOR VIII AND VWF Final Rejection OCTAPHARMA AG
18006110 ECHINOCANDIN DRUG IMPURITY, AND PREPARATION AND PURIFICATION METHODS AND USE THEREOF Non-Final OA Shanghai Techwell Biopharmaceutical Co., Ltd
18016855 STABLE FORMULATIONS OF ANTI-CANCER PEPTIDES Non-Final OA Oncolyze, Inc.
18058112 SAP AND PEPTIDOMIMETICS FOR TREATMENT OF EYE DISEASE Non-Final OA VIVEX BIOLOGICS GROUP, INC
17416845 NOVEL COMPOSITION Non-Final OA ARECOR LIMITED
17915812 POLYPEPTIDE FOR THE PROPHYLAXIS AND TREATMENT OF VIRAL INFECTIONS Non-Final OA PHARIS BIOTEC GMBH
17905303 TREATMENT OF VIRAL INFECTION Non-Final OA Pneumagen Limited
17777567 POLYPEPTIDE, AND PREPARATION METHOD THEREFOR AND USE THEREOF Final Rejection SHANXI JINBO BIO-PHARMACEUTICAL CO., LTD.
17697110 GLYCOSYLATED IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS Final Rejection Ablynx N.V.
17622660 COMBINATION THERAPY METHODS, COMPOSITIONS AND KITS Final Rejection FUNDACIÓ DE RECERCA CLÍNIC BARCELONA-INSTITUT D’INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month